ESG

As world leaders descended on the COP26 climate change conference in Glasgow this week, several pharma companies promoted their own ESG pledges.

First, Moderna on Monday outlined a commitment to achieve net-zero carbon emissions globally by 2030. The announcement touted a plan to use renewable or offset energy in all U.S. facilities starting this year and to implement sustainable construction for new plants in Africa and Canada. CEO Stéphane Bancel said in the press release that…

Teva announced Wednesday a $4 billion “sustainability-linked financing framework” that the company will use to refinance its debt while incentivizing its efforts to increase access to medicines in LMICs by 150%.

The Access to Medicine Foundation has independently validated the Tel Aviv-based company’s framework, which also includes a goal to reduce Scope 1 and 2 greenhouse gas emissions by 25% by 2025, the press release said.

Novartis and Sanofi have also issued bonds with rates…

Three pharmas published environmental, social and governance commitments this week.

First, BD released its 2021 Together We Advance strategy, promising to achieve carbon neutrality across direct operations by 2040, to work with supply chain partners on labor and environmental practices, and to improve ethnic and gender diversity at its management and executive levels by 1% year over year, among other measures.

Next up, GSK’s HIV subsidiary ViiV released a report conducted by…

Mentions:

Moderna will license a therapeutic candidate for an ultra-rare disease to a newly launched nonprofit “with no upfront fees” and “without any downstream payments,” the Massachusetts-based mRNA specialist announced Tuesday.

In a joint press release, Moderna said seeking a high price for this drug “is not aligned with our values”—effectively contrasting itself with other pharmas that have held on to unused intellectual property or sought premium pricing for rare disease burdens.

The…

Johnson & Johnson published on Wednesday its annual environmental, social and governance (ESG) performance report. The 2020 Health for Humanity Report highlighted the company’s Covid-19 response, global health strategy, responsible business practices, and reporting frameworks and standards.

On global health, J&J touted approvals of its Ebola vaccine and long-acting rilpivirine-containing injectable HIV treatment regimen and the company’s commitment of $50 million to support…